论文部分内容阅读
目的探讨雷替曲塞联合伊立替康二线治疗大肠癌的疗效及安全性。方法 58例大肠癌患者,随机分成实验组和对照组,各29例。对照组采取FOLFIRI治疗方案,实验组采取雷替曲塞与伊立替康联合治疗方案,对两组患者的治疗效果以及不良反应情况进行比较和分析。结果实验组患者中完全缓解0例,部分缓解12例,稳定10例,进展7例,治疗总有效率为41.4%;对照组患者中完全缓解0例,部分缓解6例,稳定8例,进展15例,治疗总有效率为20.7%;实验组总有效率明显高于对照组,差异有统计学意义(P<0.05)。对照组患者中出现恶心、呕吐患者6例,腹泻3例,血小板减少5例,不良反应发生率为48.3%,实验组患者中出现恶心、呕吐患者10例,腹泻6例,血小板减少6例,不良反应发生率为75.9%;实验组不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论在二线治疗大肠癌的方案中,可采取雷替曲塞联合伊立替康进行治疗,其治疗效果良好,安全性高,是临床上合理有效的治疗方法 ,值得临床推广和应用。
Objective To investigate the efficacy and safety of raltetrazole and irinotecan in the treatment of colorectal cancer. Methods 58 cases of colorectal cancer patients were randomly divided into experimental group and control group, each of 29 cases. The control group to take FOLFIRI treatment program, the experimental group to take raltitrexed and irinotecan combined treatment regimen, the two groups of patients treated and adverse reactions were compared and analyzed. Results In the experimental group, there were 0 patients in complete remission, 12 patients in partial remission, 10 in stable and 7 in progression. The total effective rate was 41.4% in control group, 0 in complete remission, 6 in partial remission and 8 in stable. 15 cases, the total effective rate was 20.7%; experimental group total effective rate was significantly higher than the control group, the difference was statistically significant (P <0.05). In the control group, there were 6 patients with nausea and vomiting, 3 with diarrhea, 5 with thrombocytopenia and 48.3% with adverse reactions. Among the patients in the control group, nausea and vomiting occurred in 10 patients, diarrhea in 6 and thrombocytopenia in 6, The incidence of adverse reactions was 75.9%. The incidence of adverse reactions in the experimental group was significantly lower than that in the control group (P <0.05). Conclusions In the second-line treatment of colorectal cancer, raltitrexed and irinotecan can be taken for treatment. The treatment effect is good and the safety is high. It is a clinically rational and effective treatment and is worthy of clinical promotion and application.